Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia
Our concept of cancer latency, the interval from when a cancer starts until it is diagnosed, has changed dramatically. A prior widely-used definition was the interval between an exposure to a cancer-causing substance and cancer diagnosis.
The most challenging part of NGS-based IGHV analysis in CLL concerns the interpretation of the findings rather than the analysis per se. ERIC and EuroClonality-NGS are working hard on addressing open issues and on standardization. See Davi et al., Leukemia 2020, doi: 10.1038/s41375-020-0923-9.
Binod Dhakal, Anita D'Souza, Saurabh Chhabra, Parameswaran Hari, Medical College of Wisconsin Milwaukee, WI, USA